VJOncology is committed to improving our service to you

ASCO 2020 | Thoughts on the RAMES study in mesothelioma

VJOncology is committed to improving our service to you

Sanjay Popat

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, reviews data from the Phase II RAMES study (NCT03560973) which evaluated the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in patients with relapsed, advanced mesothelioma. He also discusses the next steps for this regimen in light of the impending CheckMate-743 data (NCT02899299). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter